Clinical trials: Aggressive Behaviour
Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas
Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma with heterogeneity in its clinical presentations, biological behaviour and response to therapy (1-4).
- Trial name
- NCT07804173
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Anger, Hostility
Two Anger Management Programs for Teens.
The general aim of the proposed pilot study is to evaluate the the efficacy of mind-body bridging (MBB) for anger management compared with the Real Deal anger management program, in helping adolescents control or reduce their…
- Conditions
- Anger, Hostility, Aggression
- Trial name
- NCT02001246
- Testing
- Real Deal program for Anger Management, Mind-body Bridging (MBB) program
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Utah
Aggression
NIH R01 Friend to Friend With Coaching
This study examines the effectiveness of the Friend to Friend (F2F) program when conducted by teachers and counselors with active coaching from the research team.
- Trial name
- NCT04164472
- Testing
- Friend to Friend (F2F) with Coaching
- Where
- United States
- Volunteers
- 5,250 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Lymphoma, Large B-Cell, Diffuse
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly…
- Trial name
- R-Pola-Glo (NCT05798156)
- Testing
- Glofitamab, Rituximab, Obinutuzumab
- Where
- 28 sites in Austria, Germany
- Volunteers
- 125 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Relapsing-Remitting Multiple Sclerosis
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
A multicentre controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and autologous Hematopoietic Stem Cell Transplantation (aHSCT).
- Trial name
- COAST (NCT04971005)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Ocrelizumab, Alemtuzumab
- Where
- 2 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Aggressive Periodontitis
Gingival Crevicular Fluid Levels Of Monocyte Chemoattractant Protein-1
The aim of this study is to estimate GCF MCP-1 levels of healthy and Aggressive periodontitis (AgP) subjects and to compare MCP-1 levels between Localized AgP (LAgP) and Generalized AgP (GAgP) to establish its predictive…
- Trial name
- MCP-1 (NCT02927704)
- Testing
- Gingival crevicular fluid (GCF) sample
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Abant Izzet Baysal University
Dermoid
Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
- Trial name
- MP-VAC-206 (NCT06219733)
- Testing
- Vactosertib, Imatinib
- Where
- South Korea
- Sponsor
- MedPacto, Inc.
Lymphoma, Large B-Cell, Diffuse
Durvalumab in DLBCL After Autologous Transplant
The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.
- Trial name
- IDA-D (NCT03241017)
- Testing
- Durvalumab
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Autism Spectrum Disorder
VGN-Ex05e in Patients With Autism Spectrum Disorder Associated With Severe Self-Injurious and Aggressive Behaviors
To evaluate the safety and tolerability of intracerebral injection of VGN-Ex05e in the nucleus accumbens of patients with autism spectrum disorder.
- Trial name
- NCT07433517
- Testing
- VGN-Ex05e
- Volunteers
- 6 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Vitamin D 25-Hydroxylase Deficiency, Lymphoma Non-Hodgkin
High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma
The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly…
- Trial name
- NCT07366450
- Testing
- High-Dose Loading Ergocalciferol, Standard Weekly Ergocalciferol
- Where
- Thailand
- Volunteers
- 52 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Aggressive Periodontitis, Generalized
Periodontal Debridement Associated With Systemic Antibiotics and Single/Repeated PDT to Treat Aggressive Periodontitis
The aim of this project is to compare the efficacy and the local effect of the association of single or repeated application of photodynamic therapy (PDT) with antibiotic agents using Amoxicillin + Metronidazole or Clarithromycin…
- Trial name
- NCT03132714
- Testing
- Full-mouth ultrasonic debridement, Amoxicillin 500mg, Metronidazole 400mg
- Where
- Brazil
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Stress Disorders, Post-Traumatic, Aggression
Manage Emotions to Reduce Aggression (MERA)
Post-traumatic stress disorder (PTSD) is one of the most prevalent mental health conditions affecting Veterans who have served since 9/11. Veterans with PTSD report difficulty controlling impulsive aggression (IA).
- Conditions
- Stress Disorders, Post-Traumatic, Aggression, Emotion Regulation
- Trial name
- MERA (NCT04793776)
- Testing
- Manage Emotions to Reduce Aggression, Present Centered Psychotherapy
- Where
- 2 sites in United States
- Volunteers
- 233 people
- Sponsor
- VA Office of Research and Development
Cyberbullying
Building Respectful Online Space (BROS): Evaluating a Co-designed Anti-cyberbullying Intervention Among Adolescents
Background: The growing prevalence of cyberbullying throughout the world indicates the importance of anti-cyberbullying interventions, especially for adolescents.
- Trial name
- NCT06796621
- Testing
- Building Respectful Online Space (BROS), Healthy diet education program
- Where
- Hong Kong
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Violent Aggressive Behavior, Mediation
Impact of a Mediator for Patient Intake in Emergency Departments
Violence in the workplace is becoming a serious phenomenon in the contemporary world of work. Hospital staff, like any employee working in contact with the public, is particularly exposed to this violence.
- Trial name
- MEDIA (NCT03139110)
- Testing
- Presence of a mediator in the emergency departments
- Where
- 4 sites in France
- Volunteers
- 2,378 people
- Sponsor
- Hospices Civils de Lyon
Intrabony Periodontal Defect
Perforated Collagen Membrane With Nanohydroxyapatite for Intrabony Defects
The ultimate goal of periodontal therapy is the regeneration of periodontal tissues which have been destroyed due to periodontal disease.
- Trial name
- NCT03399279
- Testing
- Open flap debridment, Perforated collagen membrane, Occlusive membrane
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Diffuse Large B-Cell Lymphoma
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
The STORM-trial consists of two parts. In the part I (dose escalation of Temsirolimus) the primary objective is to establish a maximum tolerated dose of Temsirolimus in combination with Rituximab and DHAP.
- Trial name
- STORM (NCT01653067)
- Testing
- Rituximab, Temsirolimus, DHAP, intravenous
- Where
- 9 sites in Germany
- Volunteers
- 88 people
- Sponsor
- Mathias Witzens-Harig
Hyperuricemia
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with…
- Trial name
- GRAAL2 (NCT00664144)
- Testing
- Rasburicase (SR29142)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Lymphoma
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for non-Hodgkin's lymphoma.
- Trial name
- NCT00005867
- Testing
- bleomycin sulfate, CHOP regimen, cyclophosphamide
- Where
- 46 sites in United Kingdom
- Volunteers
- 310 people
- Sponsor
- Lymphoma Trials Office
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
STEMI
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
The primary objective of this study is to assess whether an aggressive quality improvement intervention strategy will decrease time from hospital presentation to first balloon inflation in non-transfer patients with acute ST…
- Trial name
- RAPID-PCI (NCT01625104)
- Testing
- Non Intervention, Agressive Intervention Process Improvement Strategies
- Where
- United States
- Volunteers
- 882 people
- Sponsor
- University of Michigan